NVAX

#2240
Novavax Inc
8.39 USD
+3.45%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
8.39
8.39
Faixa anual
5.80
11.97
Mudança diária
+3.45%
Mudança mensal
-19.09%
Mudança em 6 meses
-6.15%
Mudança anual
+31.30%
Fechamento anterior
8.11
Abrir
8.39
Bid
Ask
Mínimo
8.39
High
8.39
Volume
93
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas Dividendos
Trimestral Ano
  • Market Capitalization 1.37 B
  • Employee 749
  • Founded 1987
  • CEO John C. Jacobs
  • Website www.novavax.com
  • Headquarter Delaware, United States
  • FIGI BBG000NVSBL7
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
2.6
Price to sales ratio
1.04

Novavax Inc

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

Notícias